FRAMINGHAM (09/24/2003) - In a US$600-million deal set to close this month, Genzyme Corp. will acquire SangStat Medical Corp. A global biotechnology company focused on immunology, SangStat's pipeline complements Genzyme's work in immune-mediated diseases. The $22.50-per-share transaction amount represents an approximately 45-percent premium over the closing price of SangStat's shares on Aug. 1.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.